The Impact of Body Mass Index on Treatment Response to Secukinumab for Patients With Hidradenitis Suppurativa: A Post-Hoc Analysis of the SUNSHINE and SUNRISE Trials
Amit Garg,1 Afsaneh Alavi,2 Farida Benhadou,3 Angel S. Byrd,4 Vincenzo Bettoli,5 Ryan Sullivan,6 Ivette Alarcon,7 Iryna Lobach,7 Christine-Elke Ortmann,7 Magdalena B. Wozniak,8 Raja Sivamani9,10,11,12
The Impact of Body Mass Index on Treatment Response to Secukinumab for Patients With Hidradenitis Suppurativa: A Post-Hoc Analysis of the SUNSHINE and SUNRISE Trials
Amit Garg,1 Afsaneh Alavi,2 Farida Benhadou,3 Angel S. Byrd,4 Vincenzo Bettoli,5 Ryan Sullivan,6 Ivette Alarcon,7 Iryna Lobach,7 Christine-Elke Ortmann,7 Magdalena B. Wozniak,8 Raja Sivamani9,10,11,12
1Northwell Health; New Hyde Park, NY, USA; 2Department of Dermatology, Mayo Clinic, Rochester, MN, USA; 3Department of Dermatology, Hôpitaux Universitaires de Bruxelles, Université libre de Bruxelles (ULB), Brussels, Belgium; 4Department of Dermatology, Howard University College of Medicine, Washington, D.C., USA; 5Department of Medical Sciences, O.U. of Dermatology, Azienda Ospedaliera – University of Ferrara, Ferrara, Italy; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 7Novartis Pharma AG, Basel, Switzerland; 8Novartis Ireland Ltd, Dublin, Ireland; 9Integrative Skin Science and Research, Sacramento, California, USA; 10Zen Dermatology, Sacramento, California, USA; 11Department of Dermatology, University of California-Davis, Sacramento, California, USA; 12College of Medicine, California Northstate University, Elk Grove, California, USA
Objective:
To evaluate the efficacy and safety of secukinumab at 16 and 52 weeks in patients with moderate-to-severe hidradenitis suppurativa (HS) grouped by BMI.
Methods:
This post-hoc analysis evaluated participants from the phase 3 SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) trials by baseline BMI subgroups (underweight/healthy weight, <25 kg/m2; overweight/obese, ≥25 kg/m2). Through Week 16, patients received either secukinumab 300 mg every 2 (SECQ2W) or 4 weeks (SECQ4W) or placebo (PBO); after Week 16, all patients received either dose of secukinumab.1 Efficacy was evaluated through Week 52 using Hidradenitis Suppurativa Clinical Response (HiSCR) 50 and abscess and inflammatory nodule (AN) count. Safety was evaluated by incidence of adverse events.
Results:
Of 1083 evaluable patients, 189 (17.5%) were underweight/had a healthy weight, and 894 (82.5%) were overweight/obese. Achievement of HiSCR50 at Week 16 was numerically greater in patients receiving SECQ2W or SECQ4W compared with PBO, respectively, in underweight/healthy weight (46.6%, 44.6%, 39.1%) and overweight/obese (45.0%, 44.4%, 32.4%) groups. Greater improvements in AN count among patients receiving SECQ2W or SECQ4W compared with PBO, respectively, were observed for both underweight/healthy weight patients (−56.3%, −39.0%, −23.6%) and overweight/obese patients (−43.7%, −45.8%, −24.0%) at Week 16. Improvements from secukinumab increased through Week 52. Similar safety was observed across BMI subgroups through Week 52.
Conclusions:
Across BMI subgroups, secukinumab was effective in improving HS disease activity vs PBO at Week 16. Treatment responses were sustained or improved through Week 52, and the safety profile was consistent across subgroups.
Saverio Minervini